• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

mortalin通过调节p53的中心体定位来控制中心体复制。

Mortalin controls centrosome duplication via modulating centrosomal localization of p53.

作者信息

Ma Z, Izumi H, Kanai M, Kabuyama Y, Ahn N G, Fukasawa K

机构信息

Department of Cell Biology, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0521, USA.

出版信息

Oncogene. 2006 Aug 31;25(39):5377-90. doi: 10.1038/sj.onc.1209543. Epub 2006 Apr 17.

DOI:10.1038/sj.onc.1209543
PMID:16619038
Abstract

Abnormal amplification of centrosomes, commonly found in human cancer, is the major cause of mitotic defects and chromosome instability in cancer cells. Like DNA, centrosomes duplicate once in each cell cycle, hence the defect in the mechanism that ensures centrosome duplication to occur once and only once in each cell cycle results in abnormal amplification of centrosomes and mitotic defects. Centrosomes are non-membranous organelles, and undergo dynamic changes in its constituents during the centrosome duplication cycle. Through a comparative mass spectrometric analysis of unduplicated and duplicated centrosomes, we identified mortalin, a member of heat shock protein family, as a protein that associates preferentially with duplicated centrosomes. Further analysis revealed that mortalin localized to centrosomes in late G1 before centrosome duplication, remained at centrosomes during S and G2, and dissociated from centrosomes during mitosis. Overexpression of mortalin overrides the p53-dependent suppression of centrosome duplication, and mortalin-driven centrosome duplication requires physical interaction between mortalin and p53. Moreover, mortalin promotes dissociation of p53 from centrosomes through physical interaction. The p53 mutant that lacks the ability to bind to mortalin remains at centrosomes, and suppresses centrosome duplication in a transactivation function-independent manner. Thus, our present findings not only identify mortalin as an upstream molecule of p53 but also provide evidence for the involvement of centrosomally localized p53 in the regulation of centrosome duplication.

摘要

中心体异常扩增在人类癌症中普遍存在,是癌细胞有丝分裂缺陷和染色体不稳定的主要原因。与DNA一样,中心体在每个细胞周期中复制一次,因此确保中心体在每个细胞周期中仅复制一次的机制缺陷会导致中心体异常扩增和有丝分裂缺陷。中心体是无膜细胞器,在中心体复制周期中其组成成分会发生动态变化。通过对未复制和已复制中心体的比较质谱分析,我们鉴定出热休克蛋白家族成员mortalin是一种优先与已复制中心体结合的蛋白质。进一步分析表明,mortalin在中心体复制前的G1晚期定位于中心体,在S期和G2期仍留在中心体,在有丝分裂期间从中心体解离。mortalin的过表达克服了p53对中心体复制的依赖性抑制,并且mortalin驱动的中心体复制需要mortalin与p53之间的物理相互作用。此外,mortalin通过物理相互作用促进p53从中心体解离。缺乏与mortalin结合能力的p53突变体仍留在中心体,并以独立于反式激活功能的方式抑制中心体复制。因此,我们目前的发现不仅将mortalin鉴定为p53的上游分子,还为中心体定位的p53参与中心体复制调控提供了证据。

相似文献

1
Mortalin controls centrosome duplication via modulating centrosomal localization of p53.mortalin通过调节p53的中心体定位来控制中心体复制。
Oncogene. 2006 Aug 31;25(39):5377-90. doi: 10.1038/sj.onc.1209543. Epub 2006 Apr 17.
2
Direct evidence for the role of centrosomally localized p53 in the regulation of centrosome duplication.中心体定位的p53在中心体复制调控中作用的直接证据。
Oncogene. 2007 May 3;26(20):2939-44. doi: 10.1038/sj.onc.1210085. Epub 2006 Oct 30.
3
Difference in the centrosome duplication regulatory activity among p53 'hot spot' mutants: potential role of Ser 315 phosphorylation-dependent centrosome binding of p53.p53“热点”突变体之间中心体复制调控活性的差异:p53的Ser 315磷酸化依赖性中心体结合的潜在作用。
Oncogene. 2001 Oct 18;20(47):6851-63. doi: 10.1038/sj.onc.1204848.
4
Loss of p53 and centrosome hyperamplification.p53缺失与中心体过度扩增。
Oncogene. 2002 Sep 9;21(40):6234-40. doi: 10.1038/sj.onc.1205707.
5
Centrosome amplification, chromosome instability and cancer development.中心体扩增、染色体不稳定与癌症发展。
Cancer Lett. 2005 Dec 8;230(1):6-19. doi: 10.1016/j.canlet.2004.12.028.
6
Physical and functional interaction between mortalin and Mps1 kinase.mortalin与Mps1激酶之间的物理和功能相互作用。
Genes Cells. 2007 Jun;12(6):797-810. doi: 10.1111/j.1365-2443.2007.01091.x.
7
Centrosome number is controlled by a centrosome-intrinsic block to reduplication.中心体的数量由一种阻止中心体重复复制的内在机制所控制。
Nat Cell Biol. 2003 Jun;5(6):539-44. doi: 10.1038/ncb993.
8
Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint.基因毒性应激会导致在G1/S细胞周期检查点失活的乳腺癌细胞系中出现中心体扩增。
Oncogene. 2004 May 20;23(23):4068-75. doi: 10.1038/sj.onc.1207568.
9
Induction of centrosome amplification and chromosome instability in p53-deficient lung cancer cells exposed to benzo[a]pyrene diol epoxide (B[a]PDE).暴露于苯并[a]芘二醇环氧化物(B[a]PDE)的p53缺陷型肺癌细胞中中心体扩增和染色体不稳定性的诱导。
J Pathol. 2008 Nov;216(3):365-74. doi: 10.1002/path.2422.
10
Inhibition of BRCA1 in breast cell lines causes the centrosome duplication cycle to be disconnected from the cell cycle.在乳腺细胞系中抑制BRCA1会导致中心体复制周期与细胞周期脱节。
Oncogene. 2006 Jan 12;25(2):298-303. doi: 10.1038/sj.onc.1209028.

引用本文的文献

1
Identification of Mortalin as the Main Interactor of Mycalin A, a Poly-Brominated C-15 Acetogenin Sponge Metabolite, by MS-Based Proteomics.通过基于 MS 的蛋白质组学鉴定 Mycalin A(一种多溴化 C-15 乙酰氧基海绵代谢产物)的主要相互作用蛋白为 Mortalin。
Mar Drugs. 2024 Jan 23;22(2):52. doi: 10.3390/md22020052.
2
Mortalin: Protein partners, biological impacts, pathological roles, and therapeutic opportunities.mortalin:蛋白质伴侣、生物学影响、病理作用及治疗机会。
Front Cell Dev Biol. 2023 Feb 2;11:1028519. doi: 10.3389/fcell.2023.1028519. eCollection 2023.
3
Identification of a new member of Mortaparib class of inhibitors that target mortalin and PARP1.
鉴定靶向mortalin和PARP1的Mortaparib类抑制剂的一个新成员。
Front Cell Dev Biol. 2022 Sep 12;10:918970. doi: 10.3389/fcell.2022.918970. eCollection 2022.
4
Comparative computational and experimental analyses of some natural small molecules to restore transcriptional activation function of p53 in cancer cells harbouring wild type and p53 mutant.一些天然小分子在携带野生型和p53突变体的癌细胞中恢复p53转录激活功能的比较计算和实验分析。
Curr Res Struct Biol. 2022 Sep 13;4:320-331. doi: 10.1016/j.crstbi.2022.09.002. eCollection 2022.
5
Why is Mortalin a Potential Therapeutic Target for Cancer?为什么mortalin是癌症的一个潜在治疗靶点?
Front Cell Dev Biol. 2022 Jun 29;10:914540. doi: 10.3389/fcell.2022.914540. eCollection 2022.
6
GRP75-driven, cell-cycle-dependent macropinocytosis of Tat/pDNA-Ca nanoparticles underlies distinct gene therapy effect in ovarian cancer.GRP75 驱动的、细胞周期依赖性的 Tat/pDNA-Ca 纳米颗粒巨胞饮作用是卵巢癌细胞中不同基因治疗效果的基础。
J Nanobiotechnology. 2022 Jul 20;20(1):340. doi: 10.1186/s12951-022-01530-6.
7
SHetA2 Attack on Mortalin and Colleagues in Cancer Therapy and Prevention.SHetA2在癌症治疗与预防中对mortalin及相关蛋白的作用
Front Cell Dev Biol. 2022 Feb 23;10:848682. doi: 10.3389/fcell.2022.848682. eCollection 2022.
8
HSP70 and HSP90 in Cancer: Cytosolic, Endoplasmic Reticulum and Mitochondrial Chaperones of Tumorigenesis.癌症中的热休克蛋白70和热休克蛋白90:肿瘤发生的胞质、内质网和线粒体伴侣蛋白
Front Oncol. 2022 Jan 21;12:829520. doi: 10.3389/fonc.2022.829520. eCollection 2022.
9
Similarities and Differences of Hsp70, hsc70, Grp78 and Mortalin as Cancer Biomarkers and Drug Targets.热休克蛋白 70、热休克蛋白 70 同源物、葡萄糖调节蛋白 78 和线粒体蛋白作为癌症生物标志物和药物靶点的异同。
Cells. 2021 Nov 3;10(11):2996. doi: 10.3390/cells10112996.
10
Mitochondrial HSP70 Chaperone System-The Influence of Post-Translational Modifications and Involvement in Human Diseases.线粒体 HSP70 伴侣系统-翻译后修饰的影响及其在人类疾病中的作用。
Int J Mol Sci. 2021 Jul 28;22(15):8077. doi: 10.3390/ijms22158077.